Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study
暂无分享,去创建一个
Evangelos Kontopantelis | Iain Buchan | Tim Doran | David Reeves | Darren M. Ashcroft | David A. Springate | M. Rutter | I. Buchan | D. Reeves | E. Kontopantelis | D. Ashcroft | T. Doran | D. Springate | Martin Rutter
[1] S. Wild,et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.
[2] S. Inzucchi,et al. Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2013, Diabetologia.
[3] Evangelos Kontopantelis,et al. Recorded quality of primary care for patients with diabetes in England before and after the introduction of a financial incentive scheme: a longitudinal observational study , 2012, BMJ quality & safety.
[4] J. Shaw,et al. Global estimates of the prevalence of diabetes for 2010 and 2030. , 2010, Diabetes research and clinical practice.
[5] S. Wyke,et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study , 2012, The Lancet.
[6] A B MARTIN,et al. On a patient-centered approach. , 1960, The American journal of nursing.
[7] M. Rutter,et al. Low HbA1c and mortality: causation and confounding , 2012, Diabetologia.
[8] J. Schafer,et al. Missing data: our view of the state of the art. , 2002, Psychological methods.
[9] C. Bartlett,et al. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs , 2012, Diabetic medicine : a journal of the British Diabetic Association.
[10] M. Rutter,et al. Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care. , 2011, European heart journal.
[11] Kevin A Peterson,et al. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .
[12] M. S. Kirkman,et al. Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61 , 2011 .
[13] R. Holman,et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.
[14] Diane Lacaille,et al. Systematic Review and Meta-Analysis of Validation Studies on a Diabetes Case Definition from Health Administrative Records , 2013, PloS one.
[15] S. Silverman,et al. From randomized controlled trials to observational studies. , 2009, The American journal of medicine.
[16] C. Torp‐Pedersen,et al. Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes , 2012, Diabetologia.
[17] G. Assmann,et al. The Münster Heart Study (PROCAM): total mortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in nonsmokers. , 1997, Circulation.
[18] R. Heine,et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study , 2010, The Lancet.
[19] R. Holman,et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) , 1998, BMJ.
[20] Evangelos Kontopantelis,et al. Relationship between quality of care and choice of clinical computing system: retrospective analysis of family practice performance under the UK's quality and outcomes framework , 2013, BMJ Open.
[21] André Scheen,et al. RECOMMANDATIONS 2012 EN DIABÉTOLOGIE: Prise en charge de l'hyperglycémie dans le diabète de type 2: une approche centrée sur le patient , 2012 .
[22] Evangelos Kontopantelis,et al. Withdrawing performance indicators: retrospective analysis of general practice performance under UK Quality and Outcomes Framework , 2014, BMJ : British Medical Journal.
[23] P. Nilsson. Target blood pressure in diabetes patients with hypertension —What is the accumulated evidence in 2011? , 2011, Journal of Zhejiang University SCIENCE B.
[24] J. Kastelein,et al. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. , 2008, Mayo Clinic proceedings.
[25] E. Braunwald,et al. Coronary heart disease Acute coronary syndromes and diabetes : is intensive lipid lowering beneficial ? Results of the PROVE IT-TIMI 22 trial , 2006 .
[26] S. Heymsfield,et al. Aggressive Blood Pressure Control Increases Coronary Heart Disease Risk Among Diabetic Patients , 2013, Diabetes Care.
[27] S. Wild,et al. External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? , 2013, Diabetic medicine : a journal of the British Diabetic Association.
[28] D. Reeves,et al. ClinicalCodes: An Online Clinical Codes Repository to Improve the Validity and Reproducibility of Research Using Electronic Medical Records , 2014, PloS one.
[29] Michael E. Miller,et al. Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial , 2014, Diabetes Care.
[30] John S Yudkin,et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , 2000, BMJ : British Medical Journal.
[31] A Rogier T Donders,et al. Dealing with missing outcome data in randomized trials and observational studies. , 2012, American journal of epidemiology.
[32] N. Clark,et al. Standards of Medical Care in Diabetes: Response to Power , 2006 .
[33] R. Stevens,et al. Type and accuracy of sphygmomanometers in primary care: a cross-sectional observational study. , 2011, The British journal of general practice : the journal of the Royal College of General Practitioners.
[34] S. Schinner,et al. Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .
[35] Irene Petersen,et al. Application of Multiple Imputation using the Two-Fold Fully Conditional Specification Algorithm in Longitudinal Clinical Data , 2014, The Stata journal.
[36] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[37] D. Cook,et al. Blood pressure recording bias during a period when the Quality and Outcomes Framework was introduced , 2009, Journal of Human Hypertension.
[38] T. Manolio,et al. Association of lipids and lipoprotein level with total mortality and mortality caused by cardiovascular and cancer diseases (Poland and United States collaborative study on cardiovascular epidemiology). , 1999, The American journal of cardiology.
[39] K. Khunti,et al. Association of systolic and diastolic blood pressure and all cause mortality in people with newly diagnosed type 2 diabetes: retrospective cohort study , 2012, BMJ : British Medical Journal.
[40] A. Vaag,et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials , 2011, BMJ : British Medical Journal.
[41] Michael E. Miller,et al. Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.